Press Releases

MYOS RENS Technology Announces Initiation of a Study at Kansas State University to Evaluate the Impact of Fortetropin® on Quality of Life and Activity in Geriatric Dogs

Download PDF

CEDAR KNOLLS, N.J., Feb. 27, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced that it has signed an agreement with Kansas State University College of Veterinary Medicine to evaluate the impact of Fortetropin on quality of life and activity in geriatric dogs.  The study will be performed under the supervision of Kenneth R. Harkin, DVM, DACVIM (SAIM), Professor and Section Head, Small Animal Internal Medicine.

(PRNewsfoto/MYOS RENS Technology)

This veterinary clinical study follows the announcement of positive results from a randomized, double-blind, placebo-controlled study that examined the impact of Fortetropin on recovery following tibial plateau leveling osteotomy (TPLO) surgery in dogs.  Dr. Harkin also served as the Principal Investigator for the earlier study and presented the results at the North American Veterinary Community (NAVC) Conference / VMX on January 20, 2019.

Forty (40) geriatric dogs that suffer from three of the following conditions will be recruited to participate in the study: weakness, weight loss, slowed or altered mobility, or exercise intolerance.  Twenty (20) of these dogs will be assigned to receive Fortetropin and 20 will be assigned to receive a macronutrient-matched placebo.  All of the dogs participating in the study will be fitted with an activity collar.  After two weeks of initial activity monitoring, the dogs will receive either Fortetropin or placebo for 12 weeks.  The Quality of Life (QOL) assessment will be based on the Liverpool Osteoarthritis in Dogs (LOAD) Questionnaire. 

Dr. Harkin commented, "Pet owners often remark that their dog is "slowing down" as they enter their golden years.  Although osteoarthritis is often tipped as the culprit, the loss of muscle mass associated with old age is an under-appreciated cause.  Geriatric dogs with muscle mass loss fatigue easily, which by itself can negatively impact their quality of life.  Numerous testimonials by pet owners suggest that Fortetropin supplementation has a positive influence on quality of life and activity levels in geriatric dogs.  Based on these reports and the positive results from our previous study showing improvement in recovery from orthopedic surgery, I believe that a study examining the impact of Fortetropin on geriatric dogs is warranted."

Joseph Mannello, CEO, MYOS, commented, "I believe that MYOS is uniquely positioned to address muscle health in animals.  We have a very strong intellectual property position that forms the backbone of our animal health business.  What distinguishes MYOS from its competitors is the unique formulation of our products which are supported by rigorous scientific research conducted at leading academic institutions.  We are very pleased to work with Kansas State University on another veterinary clinical research study, supporting our potential 'game-changing' efforts in animal health."

About MYOS RENS Technology Inc. 
MYOS RENS Technology Inc. (MYOS), "The Muscle Company®", is a Cedar Knolls, NJ-based advanced nutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size and lean body mass in conjunction with resistance training. MYOS believes Fortetropin has the potential to redefine existing standards of physical health and wellness. For more information, please visit

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful results of strategic initiatives, the successful launch of our products, including Qurr®, Yolked®MYOS Enteral Nutrition Formula™ and MYOS Canine Muscle Formula® products, the success of our research and development, the results of the clinical evaluation of Fortetropin® and its effects including the clinical study described herein, the ability to enter into new partnership opportunities and the success of our existing partnerships, the ability to generate the forecasted revenue stream and cash flow from sales of our products, the ability to increase our revenue and gross profit margins, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our filings with  the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700

Cision View original content to download multimedia: